Diabetes

GLP 1 Receptor Agonists and GIP-GLP 1 Receptor Agonists for People with and without Diabetes in 2024

Jeremy Gilbert, MD, FRCPC

The End of End Stage Renal Disease from Diabetes

Phil McFarlane, MD, Ph.D., FRCP(C)

Current and future roles for GLP 1 Receptor Agonists in Primary Practice

Jeremy Gilbert, MD, FRCPC

Insulin in the Management of Diabetes Mellitus – Where We’ve Come From and Where We’re Going

Nicole Pun, MD MScCH FRCPC

The Importance of Achieving Glycemic Control

Jeremy Gilbert, MD, FRCPC

Improving Adherence in the Type 2 Diabetes patient: a Mental Health Perspective

Barry Simon, MD, FRCP

Diabetes- A practical approach to the learnings from 2021

Jeremy Gilbert, MD, FRCPC

Evaluation and Treatment of the Patient with Diabetes and Atrial Fibrillation

Kim Connelly, MBBS, PhD, FSCMR, FCCS

CKD and Diabetes – The Role of SGLT2 Inhibitors in Modifying the Risk of Progressive Kidney Disease

Jordan Weinstein, MD, FRCPC

Managing Obesity: The Impact on Prediabetes and Diabetes

David Macklin, MD, CCFP